ERBB2 and non-small cell lung carcinoma: Responders treated with T-DXd (n = 36) included two patients with NSCLC with off-label ERBB2 mutations who were not assessed with IHC and four non-NSCLC patients who were HER2 IHC-negative/not assessed.